BCM
PYXS icon

Bridgeway Capital Management’s Pyxis Oncology PYXS Stock Holding History

Bridgeway Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Buy
81,260
+8,560
+12% +$12.9K ﹤0.01% 1106
2025
Q4 		$83.6K Sell
72,700
-4,000
-5% -$14.1K ﹤0.01% 1150
2025
Q3 		$170K Sell
76,700
-65,595
-46% -$94.5K ﹤0.01% 1041
2025
Q2 		$157K Buy
142,295
+61,500
+76% +$69.3K ﹤0.01% 1010
2025
Q1 		$79.2K Sell
80,795
-189,200
-70% -$252K ﹤0.01% 1079
2024
Q4 		$421K Buy
269,995
+4,700
+2% +$13.6K 0.01% 851
2024
Q3 		$974K Buy
265,295
+18,800
+8% +$65.8K 0.02% 696
2024
Q2 		$816K Buy
246,495
+15,000
+6% +$63.1K 0.02% 744
2024
Q1 		$986K Sell
231,495
-4,700
-2% -$19.8K 0.02% 748
2023
Q4 		$425K Hold
236,195
– – 0.01% 978
2023
Q3 		$470K Sell
236,195
-50,000
-17% -$116K 0.01% 895
2023
Q2 		$733K Buy
286,195
+115,900
+68% +$368K 0.02% 806
2023
Q1 		$683K Hold
170,295
– – 0.02% 810
2022
Q4 		$228K Buy
170,295
+50,000
+42% +$75K 0.01% 1059
2022
Q3 		$237K Buy
120,295
+50,000
+71% +$131K 0.01% 1102
2022
Q2 		$167K Buy
+70,295
New +$187K ﹤0.01% 1128

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's PYXS Position: Q1 2026 in Review

Bridgeway Capital Management increased its Pyxis Oncology (PYXS) stake by 12% in Q1 2026, buying an estimated $12.9K and bringing the position to 81,260 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Bridgeway Capital Management first reported a position in PYXS in Q2 2022 and has held it in 16 quarters since. The position peaked at $986K in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Bridgeway Capital Management held 81,260 shares of Pyxis Oncology worth $119K as of Q1 2026.
  • Bridgeway Capital Management bought 8,560 Pyxis Oncology shares in Q1 2026, an estimated $12.9K.
  • Pyxis Oncology made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1106 holding.
  • Bridgeway Capital Management first reported a position in Pyxis Oncology in Q2 2022 and has held it in 16 quarters since.
  • Bridgeway Capital Management's Pyxis Oncology position peaked at $986K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.